Physician profile

Jennifer L Broadt

Physician Assistant · Yakima, WA

NPI 1962869776

$423.03

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Physician Assistant

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$72.63

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $171.05 2021-2022
Alkermes, INC. $76.59 2021-2022
Teva Pharmaceuticals USA, INC. $72.63 2023 Austedo Xr
Johnson & Johnson Surgical Vision, INC. $35.13 2021
Otsuka America Pharmaceutical, INC. $22.72 2021
Astellas Pharma US INC $15.94 2021
Sunovion Pharmaceuticals INC. $15.28 2021
Indivior INC. $13.69 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jennifer L Broadt

$423.03

in general payments reported 2019-2025

Years
2021-2023
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/11226678/jennifer-l-broadt

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.